Extended Data Fig. 7: CT and PET-CT scans of responding tumours.
From: Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours
(a-d) Participant with mesothelioma and large, bulky disease (phase 1 part). RECIST 1.1 response under treatment with partial response (a) and (c) show baseline tumour assessment with bulky disease in upper mediastinum at two levels. (b) and (d) show respective significant tumour reduction at corresponding scan level at Cycle 8, Day 1 (week 16). (e, f) Participant with metastatic non-squamous NSCLC, Baseline (e) vs. Cycle 12 (f) demonstrating partial response as per RECIST 1.1. (g, h) Participant with metastatic non-squamous NSCLC (phase 2a part). Baseline (g) vs. Cycle 35 with partial response (h) as per RECIST 1.1. (i-l) Participant with metastatic urothelial cancer (phase 2a part), shown is large retroperitoneal lesion. RECIST 1.1 response with −100% reduction (complete response). (i) Baseline assessment at Screening with lesion marked by red arrow and red line. (j) Cycle 5 Day 1 assessment: Partial response. (k) PET-CT at Cycle 28 Day 1 demonstrating complete metabolic response. (l) CT scan at Cycle 45 Day 1 with continued complete response.
